A Phase 1 interventional study of Selpercatinib in Healthy, sponsored by Loxo Oncology, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.
Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as different formulations. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 56 days including the 28 days of screening period.
Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
160 mg Selpercatinib (tablet formulation) given orally on days 1 and 15.
Drug: Selpercatinib
160 mg Selpercatinib (2 X 80 mg capsule formulation) given orally on days 1 and 15.
Drug: Selpercatinib
Administered orally
Also known as: LY3527723, LOXO-292
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib
PK: Cmax of Selpercatinib
Time frame: Day 1 and Day 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 192, 240, and 312 hours (h) postdose;
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib
PK: AUC\[0-∞\] of Selpercatinib.
Time frame: Day 1 and Day 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 192, 240, and 312 hours (h) postdose;
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib
PK: AUC\[0-tlast\] of Selpercatinib
Time frame: Day 1 and Day 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 192, 240, and 312 hours (h) postdose;
| Milestone | Sequence 1 - Selpercatinib Reference/Test | Sequence 2 - Selpercatinib Test/Reference |
|---|---|---|
| Started | 112 | 112 |
| Received at least one dose of study drug | 112 | 112 |
| Completed | 112 | 111 |
| Not completed | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Milestone | Sequence 1 - Selpercatinib Reference/Test | Sequence 2 - Selpercatinib Test/Reference |
|---|---|---|
| Started | 112 | 111 |
| Completed | 100 | 104 |
| Not completed | 12 | 7 |
| Withdrew: Adverse event | 3 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Withdrawal by subject | 6 | 3 |
| Milestone | Sequence 1 - Selpercatinib Reference/Test | Sequence 2 - Selpercatinib Test/Reference |
|---|---|---|
| Started | 100 | 104 |
| Received at least one dose of study drug | 100 | 104 |
| Completed | 95 | 101 |
| Not completed | 5 | 3 |
| Withdrew: Adverse event | 4 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 |
PK: Cmax of Selpercatinib
| nanograms per milliliter (ng/mL) | 160 mg Selpercatinib (Reference) | 160 mg Selpercatinib (Test) |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib | 1520 ± 61 | 1350 ± 91 |
PK: AUC\[0-∞\] of Selpercatinib.
| nanograms*hour per milliliter (ng*hr/mL) | 160 mg Selpercatinib (Reference) | 160 mg Selpercatinib (Test) |
|---|---|---|
| PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib | 20700 ± 45 | 19300 ± 51 |
PK: AUC\[0-tlast\] of Selpercatinib
| ng*hr/mL | 160 mg Selpercatinib (Reference) | 160 mg Selpercatinib (Testt) |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib | 20200 ± 47 | 18100 ± 65 |
Collected over Baseline up to 28 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 160 mg Selpercatinib (2 x 80 mg Reference) | 0/216 (0%) | 0/216 (0%) | 0/216 (0%) |
| 160 mg Selpercatinib (1 x 160 mg Test) | 0/212 (0%) | 0/212 (0%) | 0/212 (0%) |
All enrolled participants.
| Age, Continuous(years) | Sequence 1 - Selpercatinib Reference/Test | Sequence 2: Selpercatinib Test/Reference | Total |
|---|---|---|---|
| Mean | 42.1 ± 12.3 | 42.8 ± 12.4 | 42.5 ± 12.3 |
| Sex: Female, Male(Participants) | Sequence 1 - Selpercatinib Reference/Test | Sequence 2: Selpercatinib Test/Reference | Total |
|---|---|---|---|
| Female | 53 | 53 | 106 |
| Male | 59 | 59 | 118 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1 - Selpercatinib Reference/Test | Sequence 2: Selpercatinib Test/Reference | Total |
|---|---|---|---|
| Hispanic or Latino | 35 | 36 | 71 |
| Not Hispanic or Latino | 77 | 76 | 153 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1 - Selpercatinib Reference/Test | Sequence 2: Selpercatinib Test/Reference | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 6 | 4 | 10 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 45 | 37 | 82 |
| White | 59 | 67 | 126 |
| More than one race | 1 | 3 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Sequence 1 - Selpercatinib Reference/Test | Sequence 2: Selpercatinib Test/Reference | Total |
|---|---|---|---|
| United States | 112 | 112 | 224 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Jul 2022, 8 months.
Results were first posted in Mar 2025, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Selpercatinib